首页> 美国卫生研究院文献>ISRN Pharmacology >In Vivo and In Vitro Antidiabetic Activity of Terminalia paniculata Bark: An Evaluation of Possible Phytoconstituents and Mechanisms for Blood Glucose Control in Diabetes
【2h】

In Vivo and In Vitro Antidiabetic Activity of Terminalia paniculata Bark: An Evaluation of Possible Phytoconstituents and Mechanisms for Blood Glucose Control in Diabetes

机译:Terminalia paniculata树皮的体内和体外抗糖尿病活性:对糖尿病患者可能的植物成分和血糖控制机制的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study was aimed to investigate in vivo, in vitro antidiabetic activity of aqueous extract of Terminalia paniculata bark (AETPB) and characterize its possible phytoconstituents responsible for the actions. Type 2 diabetes was induced in rats by streptozotocin-nicotinamide (65 mg/kg–110 mg/kg; i.p.) administration. Oral treatment of AETPB using rat oral needle at 100 and 200 mg/kg doses significantly (P < 0.001) decreased blood glucose and glycosylated haemoglobin levels in diabetic rats than diabetic control rats. AETPB-treated diabetic rats body weight, total protein, insulin, and haemoglobin levels were increased significantly (P < 0.001) than diabetic control rats. A significant (P < 0.001) reduction of total cholesterol and triglycerides and increase in high-density lipoprotein levels were observed in type 2 diabetic rats after AETPB administration. Presence of biomarkers gallic acid, ellagic acid, catechin, and epicatechin in AETPB was confirmed in HPLC analysis. AETPB and gallic acid showed significant (P < 0.001) enhancement of glucose uptake action in presence of insulin in muscle cells than vehicle control. Also AETPB inhibited pancreatic α-amylase and α-glucosidase enzymes. In conclusion, the above actions might be responsible for the antidiabetic activity of AETPB due to presence of gallic acid and other biomarkers.
机译:本研究旨在调查榄仁树皮(AETPB)水提物的体内,体外抗糖尿病活性,并表征其可能的作用于植物的成分。链脲佐菌素-烟酰胺(65μg/ kg–110μmg / kg;腹腔注射)可诱发大鼠2型糖尿病。与糖尿病对照大鼠相比,以100和200μmg/ kg剂量的大鼠口服针口服AETPB显着降低了糖尿病大鼠的血糖和糖基化血红蛋白水平(P <0.001)。 AETPB治疗的糖尿病大鼠的体重,总蛋白,胰岛素和血红蛋白水平显着增加(P <0.001)。在AETPB给药后的2型糖尿病大鼠中,总胆固醇和甘油三酸酯显着减少(P <0.001),高密度脂蛋白水平增加。 HPLC分析证实了AETPB中存在生物标志物没食子酸,鞣花酸,儿茶素和表儿茶素。与载体对照相比,在肌肉细胞中存在胰岛素的情况下,AEPTB和没食子酸显示出显着(P <0.001)的葡萄糖摄取作用增强。 AETPB也抑制胰腺α-淀粉酶和α-葡萄糖苷酶。总之,由于没食子酸和其他生物标志物的存在,上述作用可能是AETPB抗糖尿病活性的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号